Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| 1 |
Apple
AAPL
|
+$4.76B |
| 2 |
Microsoft
MSFT
|
+$1.4B |
| 3 |
NVIDIA
NVDA
|
+$1.4B |
| 4 |
Amazon
AMZN
|
+$1.22B |
| 5 |
Broadcom
AVGO
|
+$1.21B |
Top Sells
| 1 |
WRK
WestRock Company
WRK
|
+$316M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$181M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$150M |
| 4 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
+$139M |
| 5 |
Cadence Design Systems
CDNS
|
+$110M |
Sector Composition
| 1 | Technology | 31.06% |
| 2 | Financials | 12.83% |
| 3 | Healthcare | 11.53% |
| 4 | Consumer Discretionary | 10.45% |
| 5 | Industrials | 8.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3676
Wipro
WIT
$29.4B
| $405K | ﹤0.01% |
125,074
-68,898
| -36% | -$223K |
|
|
BOLD
3677
Boundless Bio
BOLD
$26M
| $405K | ﹤0.01% |
116,627
+5,993
| +5% | +$20.8K |
|
3678
Co-Diagnostics
CODX
$11.8M
| $402K | ﹤0.01% |
321,275
+3,895
| +1% | +$4.87K |
|
3679
Vivani Medical
VANI
$72.3M
| $401K | ﹤0.01% |
342,891
+15,008
| +5% | +$17.6K |
|
3680
Reviva Pharmaceuticals
RVPH
$30.3M
| $401K | ﹤0.01% |
278,496
+42,376
| +18% | +$61K |
|
3681
Bionano Genomics
BNGO
$23M
| $401K | ﹤0.01% |
14,714
+4,727
| +47% | +$129K |
|
3682
NSTS Bancorp
NSTS
$61.9M
| $400K | ﹤0.01% |
38,651
+9,597
| +33% | +$99.4K |
|
3683
Tigo Energy
TYGO
$114M
| $399K | ﹤0.01% |
234,893
+146,634
| +166% | +$249K |
|
3684
Laird Superfood
LSF
$62.3M
| $398K | ﹤0.01% |
80,253
+18,187
| +29% | +$90.2K |
|
|
AHT
3685
Ashford Hospitality Trust
AHT
$38M
| $398K | ﹤0.01% |
53,169
+15,888
| +43% | +$119K |
|
3686
P3 Health Partners
PIII
$28.4M
| $398K | ﹤0.01% |
20,585
+11,018
| +115% | +$213K |
|
|
EGRX
3687
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $395K | ﹤0.01% |
105,846
-2,158
| -2% | -$8.05K |
|
3688
GEN Restaurant Group
GENK
$16.5M
| $393K | ﹤0.01% |
46,496
+2,427
| +6% | +$20.5K |
|
3689
Lee Enterprises
LEE
$27.3M
| $391K | ﹤0.01% |
44,850
-5,740
| -11% | -$50K |
|
3690
Phunware
PHUN
$52.5M
| $389K | ﹤0.01% |
113,767
+30,507
| +37% | +$104K |
|
3691
ProPhase Labs
PRPH
$20.4M
| $389K | ﹤0.01% |
160,735
+13,590
| +9% | +$32.9K |
|
3692
Outset Medical
OM
$241M
| $385K | ﹤0.01% |
37,931
-584
| -2% | -$5.93K |
|
3693
Cue Biopharma
CUE
$58.6M
| $385K | ﹤0.01% |
508,827
+16,371
| +3% | +$12.4K |
|
3694
Atara Biotherapeutics
ATRA
$82.7M
| $380K | ﹤0.01% |
46,720
+4,043
| +9% | +$32.9K |
|
|
MREO
3695
Mereo BioPharma
MREO
$283M
| $379K | ﹤0.01% |
92,156
| – | – |
|
|
EH
3696
EHang Holdings
EH
$1.13B
| $374K | ﹤0.01% |
26,439
+344
| +1% | +$4.86K |
|
3697
Rani Therapeutics
RANI
$23.3M
| $372K | ﹤0.01% |
172,261
+21,527
| +14% | +$46.5K |
|
3698
OptimumBank Holdings
OPHC
$50.5M
| $372K | ﹤0.01% |
81,411
+30,202
| +59% | +$138K |
|
3699
Pathfinder Bancorp
PBHC
$92.8M
| $371K | ﹤0.01% |
23,213
-763
| -3% | -$12.2K |
|
3700
Envela
ELA
$186M
| $369K | ﹤0.01% |
67,354
-3,368
| -5% | -$18.5K |
|